Silicone Gel Vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause

Launched by STRATPHARMA AG · Jan 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying two treatments for Genitourinary Syndrome of Menopause (GSM), which can cause discomfort and other symptoms in postmenopausal women. The trial is comparing a product called StrataMGT (a silicone gel) to estrogen vaginal cream, a common treatment for GSM. The main goal is to see if StrataMGT can improve quality of life for women just as well as the estrogen cream does.

Women aged 65 to 74 who have been diagnosed with GSM and are willing to provide informed consent may be eligible to participate. They will be asked to use either StrataMGT or the estrogen cream for three months, with monthly check-ins to discuss their symptoms and any side effects. It's important to note that women who cannot use estrogen or have allergies to the ingredients in these products will not be able to join the trial. This study is currently seeking participants and aims to help improve treatment options for women experiencing GSM.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Able to provide informed consent
• • Confirmed postmenopausal age
• • Diagnosed genitourinary syndrome of menopause
• • Access to a smartphone, tablet or computer, and to a functional email address.
• Exclusion Criteria:
• • Contraindication for the use of estrogen therapy
• • Unable to provide informed consent
• • Patient unable to apply topical device
• • Allergy or intolerance to ingredients or excipients of the formulation of studied products